Evidence map›Paper›PMID 28994039›Full record

ArticleEndocrine pathology2017

Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas.

Julieann C Lee, Melike Pekmezci, Jonathan L Lavezo, Hannes Vogel, Laurence Katznelson, Merav Fraenkel, Griffith Harsh, Mohanpal Dulai, Arie Perry, Tarik Tihan

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Recurrent non-functioning pituitary adenomas: a review on the new pathological classification, management guidelines and treatment options.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018
    Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Julieann C LeeDivision of Neuropathology, Department of Pathology, University of California, 505 Parnassus Ave, Room M-551, Box 0102, San Francisco, CA, 94143, USA.
Melike PekmezciDivision of Neuropathology, Department of Pathology, University of California, 505 Parnassus Ave, Room M-551, Box 0102, San Francisco, CA, 94143, USA.
Jonathan L LavezoDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Hannes VogelDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Laurence KatznelsonDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Merav FraenkelDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Griffith HarshDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Mohanpal DulaiTrillium Health Partners, Mississauga, ON, Canada.
Arie PerryDivision of Neuropathology, Department of Pathology, University of California, 505 Parnassus Ave, Room M-551, Box 0102, San Francisco, CA, 94143, USA.
Tarik TihanDivision of Neuropathology, Department of Pathology, University of California, 505 Parnassus Ave, Room M-551, Box 0102, San Francisco, CA, 94143, USA. tarik.tihan@ucsf.edu.
Stanford University · USUniversity of California, San Francisco · USTrillium Health Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pit-1 immunostaining is not routinely used in the characterization of pituitary adenomas, and its utility in distinguishing adenomas dedicated towards the lactotroph, somatotroph, and thyrotroph lineage from null cell adenomas warrants further evaluation. Pituitary adenomas that were negative for expression of a basic panel of hormonal markers (ACTH, prolactin, and growth hormone) were further evaluated for TSH, SF-1, and Pit-1 expression using a tissue microarray. Among the 147 identified pituitary adenomas that were negative for ACTH, prolactin, growth hormone, and TSH, expression of SF-1 was present in 68 cases (46%). Of the remaining 72 cases with sufficient tissue for further analysis, four were Pit-1 positive (6% of the adenomas negative for ACTH, prolactin, growth hormone, TSH, and SF-1); the remaining 68 were potentially null cell adenomas. Two of the Pit-1-positive adenomas displayed a paranuclear CAM 5.2 staining pattern suggestive of a sparsely granulated somatotroph adenoma; however, only one case contained fibrous bodies within a majority of the adenoma cells. Our data suggests that Pit-1 can be utilized as a second tier immunostain in cases of clinically non-functioning adenomas that are immunonegative for ACTH, prolactin, growth hormone, TSH, and SF-1 in order to further segregate rare cases of Pit-1-positive adenomas from null cell adenomas. Pit-1 immunostaining can recognize rare cases of sparsely granulated somatotroph adenomas that appear immunonegative for growth hormone, as well as rare cases of other Pit-1-positive adenomas that are negative for Pit-1 lineage hormones. Overall, pituitary adenomas of the Pit-1 lineage that do not produce prolactin, growth hormone, or TSH are rare, with only four cases identified in the current study.

Indexed as

AdenomaBiomarkers, TumorHumansImmunohistochemistryPituitary NeoplasmsTranscription Factor Pit-1Biomarkers, TumorPOU1F1 protein, humanTranscription Factor Pit-1Clinically non-functioning pituitary adenomaNull cell adenomaPit-1Pituitary adenomaSF-1Silent adenomaSparsely granulated somatotroph adenomaTranscription factors

Identifiers

PMID28994039
OpenAlexW2764190321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.